Under the Paperwork Reduction Act of 1995, no persons are required to re-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		
	Filing Date		
	First Named Inventor	Andy	ZIEGLER
	Art Unit		
	Examiner Name		
	Attornov Docket Numb	or.	DUDENA0070LIS

				Attorney D	ocket Number		PHDE0400/00S	5		
				U.	S.PATENTS				Remove	
Examiner Cite Initial* Patent Number Kind Code1			Issue Date	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1 5416815 1995-05-16 Hsieh				ail					
	2	6507633	B1	2003-01-14	Elbakri, et al	l.		all		
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	e Ad	d button.		Add	_
			U.S.P	ATENT APP	LICATION PUE	BLIC	CATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Name of Patentee or Applicant F			Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20030219152	A1	2003-11-27	August			all		
If you wish	h to a	dd additional U.S. Publ	lished Ap	plication cital	tion information	plea	ase click the Ad	d buttor	n. Add	_
				FOREIGN P	ATENT DOCU	MEN	NTS		Remove	_
		Country Code ²		d Publication le4 Date	A	lame of Patente pplicant of cited locument	e or	Pages, Columns, Line where Relevant Passages or Relevar Figures Appear	76	
	1	WO 02067201	wo	A1	2002-08-29	E	Elbakri, et al.		all	
If you wis	h to a	dd additional Foreign F	atent Do	cument citati	on information i	plea	se click the Add	button	Add	_
					TERATURE DO	_			Remove	_

	Application Number		
NEODMATION DIOOLOGUEE	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Andy	ZIEGLER
Not for submission under 37 CFR 1.99)	Art Unit		
Not to Submission and or or it is sy	Examiner Name		
	Attorney Docket Numb	er	PHDE040070US

	Examiner Initials*	Cite No	(boo	include name of the aumor (in CAPTIAL LETTERS), due of the article (when appropriate), due of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
		1		DGAN, H., et al.; Ordered subsets algorithms for transmission tomography; 1999, Phys. Med. Blot.; 35-2651.						
		2		ANGE, K., et al.; Globally Convergent Algorithms for Maximum a Posteriori Transmission Tomography, 1995, IEEE [rans. on Image Processing, 4(10)1430-1450. [
If you wish to add additional non-patent iterature document citation information please click the Add button Add EXAMINER SIGNATURE Examiner Signature Date Considered						utton Add				
	*EXAMIN	XAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a								

16e Kind Code of USPTO Potent Documents at yeary USPTO_CODY or MEPP 901.04. 2 filter of licit that issued the document, by the involved own (MPD Standard ST.3). 3 for Just purpose patient found counters, the orbidation of the year of the register or temperature precede the sent ancher of the patient document. 4 find of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 2 Applicant is to place a check mark here if Exhibit familiases benefication is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date Filing Date First Number I Andry ZIEGLER Art Unit Examiner Name Attorney Docket Number I PRIDEDMONTULS

CERTIFICATION STATEMENT

Please see	37 CFR	1 97 a	nd 1 98 to	make the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas M. Lundin/	Date (YYYY-MM-DD)	2006-09-05
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.